Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4+ lymphopenia and Mycobacterium avium-intracellulare
AUTOR(ES)
Trojan, T
FONTE
Blackwell Science Inc
RESUMO
We present the case of a 39-year-old white man with a Myobacterium avium-intracellulare pulmonary infection found to have a CD4+ count of 172 cells/mm3 and diagnosed subsequently with idiopathic CD4+ lymphopenia (ICL). After receiving clathromycin for 4 months with minimal improvement, the patient was started on pegylated subcutaneous interleukin (IL)-2 at 600 000 units daily. Later, he received incrementally higher pegylated IL-2 doses until he reached a maintenance dose 3 months later of 11 million units weekly divided into three equal doses. After 5 months of therapy, the patient's chronic cough resolved completely, sputum cultures became negative for Myobacterium avium-intracellulare and the CD4+ T cell count increased to 553 cells/mm3. After 35 months of well-tolerated IL-2 treatments and no recurrence of any opportunistic infections, IL-2 treatment was stopped. CD4+ counts 6 and 9 months after discontinuing IL-2 treatment were 596 and 378 cells/mm3 respectively, and he remains asymptomatic. This report supports IL-2 treatment for ICL-associated opportunistic infections as a safe and potentially efficacious treatment option, especially when combined with more traditional treatment regimens.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2691972Documentos Relacionados
- Mycobacterium avium-intracellulare and acute abdominal pain.
- Mycotic aneurysm and disseminated Mycobacterium avium-intracellulare infection in a patient with hairy cell leukemia.
- Mycobacterium avium-intracellulare and the unpredictable course of hypercalcemia in an AIDS patient
- Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.
- Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics.